BIO-RAD LABORATORIES, INC. (BIO-B) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-28

Key Insights

CFO Roop Kalyan acquired 1,078 shares of Bio-Rad Class A common stock through vesting of restricted stock units on 04/24/2026, with total beneficial ownership reaching 2,983.895 shares, indicating continued equity accumulation by senior management.
The executive sold 420 shares at $287.84 per share on the same transaction date, suggesting either planned portfolio rebalancing or tax management rather than loss of confidence in the company.
RSU vesting represents routine compensation execution with 1,078 of 4,311 granted units vesting in the first annual installment (25%), consistent with standard four-year equity vesting schedules for senior executives.
The filing includes 62.24 shares acquired under the Employee Stock Purchase Plan on 03/31/2026, demonstrating the executive's voluntary participation in company savings programs alongside equity compensation.

Want the newest filings?

This analysis covers the filing from 2026-04-28. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-28

EVP General Counsel Courtney Enloe acquired 186 shares through vesting of restricted stock units on 04/24/2026, with total beneficial ownership reaching 826.777 shares, indicating continued equity compensation alignment with company performance.
Simultaneous sale of 77 shares at $287.84 per share suggests routine portfolio rebalancing or tax management rather than loss of confidence, as the sale represents only ~9% of vested shares acquired.
RSU grant from April 2024 vests in four equal annual installments with 186 shares vesting in the first year, demonstrating a structured long-term executive retention strategy typical for senior leadership roles.
Additional share acquisitions through Bio-Rad Employee Stock Purchase Plan (09/30/2025 and 12/31/2025) totaling ~11.79 shares show voluntary participation in company equity programs beyond required compensation.

Filed: 2026-04-23

Director Arnold Pinkston acquired 776 total shares of Bio-Rad Class A common stock through vesting of restricted stock units (369 shares on 04/21/2026 and 407 shares through an additional vesting event), indicating continued equity compensation alignment with shareholders.
The RSU vesting occurred at $0 price per share, confirming these were compensation-based equity awards rather than open market purchases, with vesting contingent on the earlier of the first anniversary or next annual stockholder meeting.
This transaction represents a routine insider equity compensation event with no significant buying or selling activity that would signal insider confidence or concern about the company's stock valuation.

Filed: 2026-04-23

Director Jeffrey L. Edwards acquired 407 shares of Bio-Rad Class A common stock on 04/21/2026 through the vesting of restricted stock units, with zero acquisition price indicating this was a compensation-related vesting event rather than a market purchase.
Edwards also received 369 additional restricted stock units on the same date, which will vest within one year or at the next annual stockholders meeting, demonstrating ongoing equity incentive compensation for board service.
The insider transaction shows routine equity compensation activity with no cash outlay, suggesting the director's stake in the company is being maintained through standard RSU vesting rather than voluntary market purchases, which is neutral from a conviction standpoint.

Filed: 2026-04-23

Director Gregory K. Hinckley acquired 407 shares of Bio-Rad Class A common stock on April 21, 2026, through the vesting of restricted stock units at no cost, bringing his total beneficial ownership to 1,215 shares.
An additional 369 restricted stock units vested on the same date, indicating a scheduled equity compensation event that will convert to shares upon the earlier of the first anniversary or the company's next annual stockholders meeting.
The transaction represents routine equity compensation vesting rather than discretionary insider buying, suggesting confidence maintenance in the company but not a strong conviction buy signal from management.

Filed: 2026-04-23

Director Melinda Litherland acquired 776 shares of Bio-Rad Class A common stock through the vesting of restricted stock units (369 shares vested on 4/21/2026, with an additional 407 shares acquired on the same date), indicating routine equity compensation rather than discretionary market purchases.
The RSU vesting structure shows a one-year vesting schedule tied to the earlier of the first anniversary or next annual shareholder meeting, which is a standard director compensation practice with no immediate cash outlay required.
This transaction represents an insider acquisition through equity compensation, which is typically viewed neutrally as it reflects predetermined compensation plans rather than speculative trading activity or loss of confidence in the company.

Other reports for BIO-RAD LABORATORIES, INC.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.